Browsing Tag
SYFOVRE
1 post
Apellis Pharmaceuticals gains 6.66% as investors bet on Q2 trial update and long-term pipeline potential
Apellis Pharmaceuticals stock jumped 6.66% as investors bet on key trial updates and undervalued biotech potential. Will FDA decisions drive more upside?